Metraipolis › archive › dc_272bc4db55af

Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase… — Europe PMC PMID:42315637

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42315637
DOI
10.1007/s00259-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-10-19T07:47:25.667Z
SHA-256 of the archived text
56e5620fbd65a7875d940ec93e07e82cb659ca3a36e2e023284290d8075d41f8
Stable URL of this page
https://metraipolis.com/documento/dc_272bc4db55af

How to cite

Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase… — Europe PMC PMID:42315637 — Europe PMC (en), https://europepmc.org/article/MED/42315637 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_272bc4db55af (Metraipolis archive dc_272bc4db55af, sha256 56e5620fbd65a7875d940ec93e07e82cb659ca3a36e2e023284290d8075d41f8)
BibTeX
@misc{dc272bc4db55af,
  title = {Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase… — Europe PMC PMID:42315637},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42315637},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_272bc4db55af; sha256 56e5620fbd65a7875d940ec93e07e82cb659ca3a36e2e023284290d8075d41f8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42315637. Agents can read the archived copy with the MCP tool read_document.